Understand the United States Prostate Cancer Patient Experience in 2023: Demographics, Impact on Quality of Life, Information-seeking Behaviors, HCP Engagement, Treatment Awareness and Experiences
24 oct. 2024 04h27 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer in the United States: Understanding the Prostate Cancer Patient Experience" report has been added to ResearchAndMarkets.com's...
Metastatic Prostate Cancer Markets, Pipeline Analysis, Epidemiology Forecast and Competition Data; 2018-2034
12 juin 2024 11h34 HE
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
18 avr. 2024 09h11 HE
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Non-metastatic Prostate Cancer (nmPC) Market, Epidemiology, and Forecast - Strategic Insight until 2032
24 janv. 2024 10h39 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032
04 janv. 2024 18h33 HE
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
US Prostate Cancer Drug Market Outlook to 2026: Comprehensive Clinical Insight on 25 FDA Approved Prostate Cancer Drugs
10 févr. 2021 03h38 HE
|
Research and Markets
Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. ...
Nubeqa®-lääkkeelle (darolutamidi) myyntilupa EU:ssa etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen eturauhassyövän uutena hoitona
30 mars 2020 11h15 HE
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 30.3.2020 klo 18.15 Nubeqa®-lääkkeelle (darolutamidi) myyntilupa EU:ssa etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen...
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
30 mars 2020 11h15 HE
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 30 MARCH 2020 at 18.15 EEST Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate...
Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen eturauhassyövän hoitoon tarkoitetulle darolutamidille
31 janv. 2020 06h30 HE
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 31.1.2020 klo 13.30 Euroopan lääkeviraston (EMA) ihmislääkekomitea (CHMP) on antanut myönteisen lausunnon suosittaen darolutamidin myyntiluvan...
Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
31 janv. 2020 06h30 HE
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 31 JANUARY 2020 at 13.30 EET The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...